Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Non-Current Deffered Revenue: 2022-2025

Historic Non-Current Deffered Revenue for Phathom Pharmaceuticals (PHAT) over the last 3 years, with Sep 2025 value amounting to $349.0 million.

  • Phathom Pharmaceuticals' Non-Current Deffered Revenue rose 8.25% to $349.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $349.0 million, marking a year-over-year increase of 8.25%. This contributed to the annual value of $333.3 million for FY2024, which is 11.16% up from last year.
  • Per Phathom Pharmaceuticals' latest filing, its Non-Current Deffered Revenue stood at $349.0 million for Q3 2025, which was up 0.57% from $347.0 million recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Non-Current Deffered Revenue registered a high of $349.0 million during Q3 2025, and its lowest value of $109.5 million during Q4 2022.
  • Its 3-year average for Non-Current Deffered Revenue is $286.2 million, with a median of $321.8 million in 2024.
  • Data for Phathom Pharmaceuticals' Non-Current Deffered Revenue shows a peak YoY soared of 173.74% (in 2023) over the last 5 years.
  • Quarterly analysis of 4 years shows Phathom Pharmaceuticals' Non-Current Deffered Revenue stood at $109.5 million in 2022, then spiked by 173.74% to $299.8 million in 2023, then grew by 11.16% to $333.3 million in 2024, then increased by 8.25% to $349.0 million in 2025.
  • Its Non-Current Deffered Revenue stands at $349.0 million for Q3 2025, versus $347.0 million for Q2 2025 and $343.8 million for Q1 2025.